Recordati Industria Chimica E Farmaceutica SpA

Recordati’s 2025 earnings beat expectations with 8.3% revenue growth, a 19.4% operating margin, and a strong rare‑disease pipeline—outpacing rivals while maintaining ESG excellence.

Recordati’s shares lift modestly after 2025 earnings, as Barclays upgrades the company to equal‑weight amid its China exit, hinting at steady fundamentals but uncertain growth.

Recordati shares dip in Milan as pharma sector sells off—find out why and how investors can navigate short‑term volatility.

Recordati’s share‑buyback and governance strategy shows how a family‑owned pharma firm can boost shareholder value while maintaining market liquidity and professional oversight.

Discover how Recordati’s niche specialty drugs, digital supply‑chain AI and ESG focus position it amid rising regulatory pressures and market commoditization.

Recordati’s Enjaymo gains traction amid EU pricing pressure, as the company balances outcome‑based contracts, supply‑chain resilience, and real‑world evidence to secure reimbursement and drive growth.

Recordati’s Milan rally shows how real‑world evidence on Castleman disease can lift a rare‑disease pharma’s stock, boosting investor confidence and positioning it for long‑term growth.

Recordati’s recent share dip reflects broader healthcare sector softness, yet the company’s strong R&D pipeline, value‑based reimbursement focus, and cost‑efficient operations keep it poised for long‑term growth.

Recordati Industria Chimica e Farmaceutica SpA, a Milan-listed pharmaceutical developer, faces a complex interplay of macroeconomic, regulatory, and competitive forces that may impact its financial trajectory, despite demonstrating solid financial h…

Recordati Industria Chimica e Farmaceutica SpA has announced the appointment of Mike McClellan as Chief Financial Officer, while also repurchasing treasury shares and investing in pediatric oncology research through the Arrigo Recordati Prize, posit…